JP2014512183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512183A5 JP2014512183A5 JP2014503979A JP2014503979A JP2014512183A5 JP 2014512183 A5 JP2014512183 A5 JP 2014512183A5 JP 2014503979 A JP2014503979 A JP 2014503979A JP 2014503979 A JP2014503979 A JP 2014503979A JP 2014512183 A5 JP2014512183 A5 JP 2014512183A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell
- extracellular domain
- individual
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 20
- 230000003834 intracellular effect Effects 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 6
- 210000000987 immune system Anatomy 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 201000010175 gallbladder cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000002471 spleen cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102000003816 Interleukin-13 Human genes 0.000 claims 2
- 108090000176 Interleukin-13 Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 claims 1
- 101000972278 Homo sapiens Mucin-6 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- -1 MAGEA Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 102100022496 Mucin-5AC Human genes 0.000 claims 1
- 102100022493 Mucin-6 Human genes 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 102100037686 Protein SSX2 Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 210000004986 primary T-cell Anatomy 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473457P | 2011-04-08 | 2011-04-08 | |
| US61/473,457 | 2011-04-08 | ||
| PCT/US2012/032322 WO2012138858A1 (en) | 2011-04-08 | 2012-04-05 | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016246100A Division JP6297129B2 (ja) | 2011-04-08 | 2016-12-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512183A JP2014512183A (ja) | 2014-05-22 |
| JP2014512183A5 true JP2014512183A5 (OSRAM) | 2015-04-09 |
| JP6066991B2 JP6066991B2 (ja) | 2017-01-25 |
Family
ID=46969548
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014503979A Expired - Fee Related JP6066991B2 (ja) | 2011-04-08 | 2012-04-05 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
| JP2016246100A Active JP6297129B2 (ja) | 2011-04-08 | 2016-12-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
| JP2018027460A Pending JP2018108091A (ja) | 2011-04-08 | 2018-02-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016246100A Active JP6297129B2 (ja) | 2011-04-08 | 2016-12-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
| JP2018027460A Pending JP2018108091A (ja) | 2011-04-08 | 2018-02-20 | キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10548921B2 (OSRAM) |
| EP (2) | EP2694640B1 (OSRAM) |
| JP (3) | JP6066991B2 (OSRAM) |
| CN (2) | CN107164330A (OSRAM) |
| AU (3) | AU2012240135B2 (OSRAM) |
| CA (1) | CA2832569A1 (OSRAM) |
| DK (1) | DK2694640T3 (OSRAM) |
| ES (1) | ES2649967T3 (OSRAM) |
| MX (2) | MX347656B (OSRAM) |
| NO (1) | NO2724929T3 (OSRAM) |
| NZ (3) | NZ723731A (OSRAM) |
| WO (1) | WO2012138858A1 (OSRAM) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2859093A4 (en) * | 2012-06-11 | 2016-08-17 | Wolf Wilson Mfg Corp | IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES |
| JP6445434B2 (ja) | 2012-08-09 | 2018-12-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| WO2014124143A1 (en) * | 2013-02-06 | 2014-08-14 | Anthrogenesis Corporation | Modified t lymphocytes having improved specificity |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN105518018B (zh) | 2013-03-15 | 2020-04-03 | 细胞基因公司 | 修饰的t淋巴细胞 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| WO2014172584A1 (en) * | 2013-04-17 | 2014-10-23 | Baylor College Of Medicine | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
| JP2016526536A (ja) * | 2013-06-14 | 2016-09-05 | ザ ユニバーシティ オブ ヒューストン システム | 修飾されたキメラ抗原受容体による腫瘍新生血管構造の標的化 |
| JP6585041B2 (ja) * | 2013-07-18 | 2019-10-02 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫細胞の能力を増強する方法 |
| CA3225453A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| ES2963718T3 (es) | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| FI3888674T3 (fi) | 2014-04-07 | 2024-07-02 | Novartis Ag | Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria |
| KR20160145802A (ko) * | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| CN107109420A (zh) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll－1嵌合抗原受体的癌症治疗 |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| JP6631865B2 (ja) * | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| CA2961636A1 (en) | 2014-09-17 | 2016-03-24 | Boris ENGELS | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| IL303247A (en) | 2014-12-29 | 2023-07-01 | Novartis Ag | Methods for preparing cells expressing a chimeric receptor antigen |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| AU2015380397B2 (en) * | 2015-01-31 | 2021-10-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| IL303543A (en) | 2015-02-18 | 2023-08-01 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN107531805A (zh) | 2015-03-05 | 2018-01-02 | 弗雷德哈钦森癌症研究中心 | 免疫调节融合蛋白及其用途 |
| BR112017020058A2 (pt) * | 2015-03-20 | 2018-06-05 | Childrens Nat Medical Ct | processo para produzir uma célula-t específica, composição, banco de células-t específicas, método de tratamento, e, banco ou instalação de armazenamento de células. |
| IL254817B2 (en) | 2015-04-08 | 2023-12-01 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| CN108473957B (zh) | 2015-04-17 | 2024-07-16 | 诺华股份有限公司 | 改善嵌合抗原受体表达细胞的功效和扩增的方法 |
| CN113106053A (zh) | 2015-04-21 | 2021-07-13 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN104910279B (zh) * | 2015-06-05 | 2019-02-22 | 重庆精准生物技术有限公司 | 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用 |
| JP7146632B2 (ja) | 2015-07-21 | 2022-10-04 | ノバルティス アーゲー | 免疫細胞の有効性および増大を改善する方法 |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| JP2018536436A (ja) | 2015-12-04 | 2018-12-13 | ノバルティス アーゲー | 免疫腫瘍学のための組成物および方法 |
| MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
| EP3416661A4 (en) | 2016-02-18 | 2020-03-04 | Enlivex Therapeutics Ltd. | COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| SG10202104509PA (en) * | 2016-03-19 | 2021-06-29 | Exuma Biotech Corp | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| CN116970630A (zh) * | 2016-08-26 | 2023-10-31 | 贝勒医学院 | 用于细胞治疗的组成型活性细胞因子受体 |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| ES2916335T3 (es) | 2016-10-20 | 2022-06-30 | Celgene Corp | Receptores de antígeno quimérico heterodimerizable basados en cereblon |
| EP3541833B1 (en) | 2016-11-17 | 2024-01-24 | 2seventy bio, Inc. | Tgf beta signal convertor |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| GB201702617D0 (en) * | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| EP3589733A1 (en) * | 2017-03-03 | 2020-01-08 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| EP3595706A1 (en) | 2017-03-17 | 2020-01-22 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| MX2019011272A (es) | 2017-03-22 | 2019-10-24 | Novartis Ag | Composiciones y metodos para inmunooncologia. |
| SG10202111394XA (en) | 2017-04-13 | 2021-12-30 | Senti Biosciences Inc | Combinatorial cancer immunotherapy |
| WO2019073299A1 (en) | 2017-10-10 | 2019-04-18 | Medicenna Therapeutics, Inc. | IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS |
| BR112020007576A2 (pt) | 2017-10-18 | 2020-09-24 | Novartis Ag | composições e métodos para degradação de proteína seletiva |
| CN118420783A (zh) * | 2017-12-06 | 2024-08-02 | 恺兴生命科技(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
| WO2019169290A1 (en) * | 2018-03-02 | 2019-09-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| AU2019231205A1 (en) | 2018-03-06 | 2020-09-24 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| WO2019232523A1 (en) * | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| US12404497B2 (en) | 2018-06-01 | 2025-09-02 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| AU2019359890B2 (en) | 2018-10-17 | 2024-10-24 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US20200147137A1 (en) * | 2018-11-08 | 2020-05-14 | WUGEN, Inc. | Compositions and methods for treatment of cancer |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| US11786553B2 (en) | 2019-03-01 | 2023-10-17 | Allogene Therapeuctics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| PH12021551861A1 (en) | 2019-03-01 | 2022-05-30 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors |
| MX2022002342A (es) | 2019-08-30 | 2022-06-14 | Univ Yale | Composiciones y metodos para suministro de acidos nucleicos a celulas. |
| KR102275668B1 (ko) * | 2019-09-26 | 2021-07-12 | 충북대학교 산학협력단 | 면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도 |
| CA3163104A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| CN114945382A (zh) | 2019-11-26 | 2022-08-26 | 诺华股份有限公司 | Cd19和cd22嵌合抗原受体及其用途 |
| AU2021227191A1 (en) | 2020-02-24 | 2022-08-25 | Allogene Therapeutics, Inc. | BCMA car-T cells with enhanced activities |
| EP4110801A1 (en) | 2020-02-25 | 2023-01-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| AU2021331785A1 (en) | 2020-08-31 | 2023-03-30 | Gennao Bio, Inc. | Compositions and methods for delivery of nucleic acids to cells |
| CN119546327A (zh) | 2022-04-08 | 2025-02-28 | 再生元制药公司 | 多部分受体和信号传导复合物 |
| CN120641131A (zh) | 2022-12-01 | 2025-09-12 | 耶鲁大学 | 用于细胞内有效载荷递送的刺激反应性无痕工程化平台 |
| CN120225568A (zh) * | 2022-12-27 | 2025-06-27 | 广州瑞风生物科技有限公司 | 一种融合蛋白及其应用 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| AU2024212695A1 (en) | 2023-01-23 | 2025-08-14 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| KR20250165594A (ko) | 2023-02-07 | 2025-11-26 | 퀠 테라퓨틱스 리미티드 | Treg 세포의 배양 방법 |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN116284449B (zh) * | 2023-02-27 | 2024-11-19 | 深圳市先康达生命科学有限公司 | 增强型TGF-βR嵌合受体及其应用 |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向ｐｓｍａ及ｃａ９之系統 |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024193687A1 (en) * | 2023-03-23 | 2024-09-26 | Nanjing Legend Biotech Co., Ltd. | Inverted cytokine receptors and methods of use thereof |
| AU2024243972A1 (en) * | 2023-04-06 | 2025-10-23 | Memorial Hospital For Cancer And Allied Diseases | Il-10 receptor antibodies and methods of use thereof |
| CN116496417B (zh) * | 2023-06-27 | 2023-10-10 | 北京市肿瘤防治研究所 | 含有膜型il7的融合蛋白及t细胞 |
| WO2025016399A1 (en) * | 2023-07-17 | 2025-01-23 | Nanjing Legend Biotech Co., Ltd. | Fusion proteins and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU695869B2 (en) * | 1993-04-06 | 1998-08-27 | Fred Hutchinson Cancer Research Center | Chimeric cytokine receptors in lymphocytes |
| JP2002516562A (ja) | 1996-03-04 | 2002-06-04 | ターゲティッド ジェネティックス コーポレイション | Ｔリンパ球のインビトロ増殖のための改変された迅速な拡大方法（「改変ｒｅｍ」） |
| US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
| CN1842346A (zh) | 2001-01-12 | 2006-10-04 | 塞托凯恩药物科学公司 | 由巨噬细胞迁移抑制因子调节细胞毒性淋巴细胞反应 |
| US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| CA2445746C (en) * | 2001-04-30 | 2012-09-18 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7235392B2 (en) | 2001-12-07 | 2007-06-26 | The Ohio State University Research Foundation | Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
| US20040138187A1 (en) | 2002-08-28 | 2004-07-15 | Reading Christopher L. | Therapeutic treatment methods |
| AU2003287451A1 (en) | 2002-11-01 | 2004-06-07 | Cell Genesys, Inc. | Cell-specific adenovirus vector comprising ebv-specific promoter |
| JP2004315381A (ja) * | 2003-04-11 | 2004-11-11 | Japan Science & Technology Agency | ナチュラルキラーＴ細胞のインターロイキン１８による刺激を利用した免疫疾患治療薬剤および治療キット、並びにＩｇＥ産生の制御方法 |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| US20070071759A1 (en) * | 2005-06-29 | 2007-03-29 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| AU2014368383B2 (en) | 2013-12-20 | 2020-01-16 | Cellectis | Method of engineering multi-input signal sensitive T cell for immunotherapy |
-
2012
- 2012-04-05 NZ NZ723731A patent/NZ723731A/en not_active IP Right Cessation
- 2012-04-05 MX MX2013011742A patent/MX347656B/es active IP Right Grant
- 2012-04-05 CA CA2832569A patent/CA2832569A1/en active Pending
- 2012-04-05 CN CN201710136120.8A patent/CN107164330A/zh active Pending
- 2012-04-05 ES ES12767723.5T patent/ES2649967T3/es active Active
- 2012-04-05 EP EP12767723.5A patent/EP2694640B1/en active Active
- 2012-04-05 NZ NZ616405A patent/NZ616405A/en not_active IP Right Cessation
- 2012-04-05 EP EP17190649.8A patent/EP3305890B1/en active Active
- 2012-04-05 MX MX2017005885A patent/MX380522B/es unknown
- 2012-04-05 WO PCT/US2012/032322 patent/WO2012138858A1/en not_active Ceased
- 2012-04-05 CN CN201280024856.1A patent/CN103582699B/zh active Active
- 2012-04-05 US US14/110,582 patent/US10548921B2/en active Active
- 2012-04-05 NZ NZ710810A patent/NZ710810A/en not_active IP Right Cessation
- 2012-04-05 JP JP2014503979A patent/JP6066991B2/ja not_active Expired - Fee Related
- 2012-04-05 DK DK12767723.5T patent/DK2694640T3/da active
- 2012-04-05 AU AU2012240135A patent/AU2012240135B2/en not_active Ceased
-
2013
- 2013-08-08 NO NO13003957A patent/NO2724929T3/no unknown
-
2016
- 2016-11-01 AU AU2016253549A patent/AU2016253549B2/en not_active Ceased
- 2016-12-20 JP JP2016246100A patent/JP6297129B2/ja active Active
-
2018
- 2018-02-20 JP JP2018027460A patent/JP2018108091A/ja active Pending
- 2018-07-04 AU AU2018204850A patent/AU2018204850B2/en not_active Ceased
-
2020
- 2020-01-15 US US16/743,968 patent/US11717538B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014512183A5 (OSRAM) | ||
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP6888225B2 (ja) | 改善された特異性を有する改変型ｔリンパ球 | |
| Houot et al. | T-cell–based immunotherapy: adoptive cell transfer and checkpoint inhibition | |
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| Gill et al. | Chimeric antigen receptor T cell therapy: 25 years in the making | |
| Dar et al. | Insights into the relationship between toll like receptors and gamma delta T cell responses | |
| JP2017513470A5 (OSRAM) | ||
| JP2018522567A5 (OSRAM) | ||
| ES2837628T3 (es) | Linfocitos T modificados | |
| JP2016513458A5 (OSRAM) | ||
| RU2016143388A (ru) | Экспрессия трансгенов, регулируемая лекарственным средством | |
| Leisegang et al. | T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy | |
| Zhang et al. | Genetic engineering with T cell receptors | |
| WO2019210293A1 (en) | Car t cells with one or more interleukins | |
| US20250163128A1 (en) | T cell expressing an fc gamma receptor and methods of use thereof | |
| JP2018531016A5 (OSRAM) | ||
| Prinzing et al. | CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? | |
| Pedrazzoli et al. | Is adoptive T-cell therapy for solid tumors coming of age? | |
| Hanagiri et al. | Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes | |
| EP4130028A1 (en) | Engineered tcr complex and methods of using same | |
| JPWO2020163634A5 (OSRAM) | ||
| US20250066447A1 (en) | Engineered tcr complex and methods of using game | |
| JP2018522594A5 (OSRAM) | ||
| Shamalov et al. | Adoptive T-cell immunotherapy: perfecting self-defenses |